Pfizer Finds Heart Risk With Celebrex - Stock Plunges
December 17, 2004
Celebrex News Alerts and Lawyer Updates
Pfizer Inc. said Friday, December 17, 2004, that it had found an
increased risk of heart problems with patients taking its painkiller
Celebrex, a drug that is in the same class as the Vioxx, which was
pulled from the market in September because of safety concerns.
Pfizer said the increased risk was found in one of
two long-term cancer prevention trials, while the other trial showed
no increased risk.
Merck & Co.’s abrupt withdrawal of Vioxx from the market had
increased scrutiny on other COX-2 inhibitors – specifically Celebrex, made by Pfizer Inc. The European Medicines Agency in
London recently stated that it would review safety data on all drugs
of the class; the FDA has indicated previously it will be doing the
same; and in the October 6, 2004, edition of the New England Journal
of Medicine, two experts stated that many more people may be at risk
from taking other popular drugs of the same class.
Merck withdrew its bestselling
painkiller from the market after a placebo-controlled study found
that the drug increased the risk of heart attack and stroke among
users. Like Vioxx, Celebrex is part of a group of prescription
medicines called COX-2 inhibitors that are supposed to be safer for
treating arthritis pain than over-the-counter remedies like aspirin,
ibuprofen and naproxen.
European medicines regulators will
review all available long-term studies of drugs in the COX-2
inhibitors class. In addition to celecoxib (Celebrex), the
regulators will review studies of valdecoxib, marketed as Bextra,
and also made by Pfizer Inc. which is called Bextra. Both are made
by Pfizer Inc.
In the two New England Journal of
Medicine articles, both scientists stated that research into the way
COX-2 inhibitors work indicates that Celebrex and similar drugs
could also cause negative cardiovascular events similar to those
linked to Vioxx, and that doctors should avoid prescribing them for
patients at risk of heart disease.
TO REACH
CELEBREX LAWYERS / ATTORNEYS
If you or a loved one have
suffered from the dangerous side effects of Celebrex, you should
consider receiving a free legal evaluation from an experienced
Celebrex lawyer. For a free evaluation of your situation please
complete the following form and a Celebrex attorney will contact you
promptly - free of charge.
CELEBREX NEWS
Pfizer Finds Heart Risk With Celebrex
December 17, 2004, ABC News
Pfizer Inc. said Friday it two tests showed an increased risk of
heart problems with patients taking its painkiller Celebrex, a drug
that is in the same class as the Vioxx, which was pulled from the
market in September because of safety concerns.
Arthritis Drug Fears Escalate, Celebrex Concerns Listed
October 24, 2004, Stuff.co.nz
Preliminary
data shows may be slightly more likely to cause circulatory problems
than Vioxx, which was pulled from pharmacies this month.
EMEA to review COX-2 inhibitors
October 22, 2002, European Medicines Agency
Following the worldwide withdrawal of Vioxx (rofecoxib), the
European Medicines Agency (EMEA) has been asked by the European
Commission, as a precautionary measure, to conduct a review of COX-2
inhibitor medicines.
Pfizer Falls On Celebrex Concerns
October 8, 2004, CBS Marketwatch
... shares dove more than 7 percent Thursday at one point after
editorials in the New England Journal of Medicine indicated its drug
Celebrex could possibly cause cardiovascular problems similar to
those of Merck's Vioxx...
Scientists
Call For Fresh Look At Celebrex
October 8, 2004, Salt Lake Tribune
Scientists in the United States and Britain are calling for a fresh
look at Celebrex and other medications similar to Vioxx, the
arthritis drug pulled from the ...
Other Drugs Besides Vioxx May Raise Heart Risks, Report Suggests
Oct 6, 2004, WTVM,
GA
... A University of Pennsylvania cardiologist says he thinks the
problem with Vioxx may also apply to Celebrex and to a newer Pfizer
drug, Bextra. ...
Contact us for
Celebrex Lawyer Representation in Los Angeles, CA; Baltimore,
MD; Boston, MA, St. Paul, MN; St. Louis, MO; New York, NY; Raleigh,
Greensboro, Charlotte, NC; Scranton Wilkes-Barre Harrisburg
Philadelphia, PA; Dallas, TX and Alabama
| Arkansas | Arizona | California | Colorado | Connecticut | DC
Washington | Delaware | Florida | Georgia | Hawaii | Iowa | Idaho |
Illinois | Indiana | Kansas | Kentucky | Louisiana | Massachusetts |
Maryland | Maine | Michigan | Minnesota | Missouri | Mississippi |
Montana | North Carolina | North Dakota | Nebraska | New Hampshire |
New Jersey | New Mexico | Nevada | New York | Ohio | Oklahoma |
Oregon | Pennsylvania | Rhode Island | South Carolina | South Dakota
| Tennessee | Texas | Utah | Virginia | Vermont | Washington |
Wisconsin | West Virginia | Wyoming | Canada | International
Top of Page
|
